Proliferation marker Ki-67 in early breast cancer.

By A. Urruticoechea, I. Smith, Mitchell Dowsett. Journal of Clinical Oncology, 2005

766 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. (2007, background): “It is logical that the change in tumor cell Ki67 expression might be related to treatment benefi t, and it is well known (and confi rmed here) that tumor cell Ki67 expression before treatment is related to prognosis (6, 7 ); by extrapolation we infer that measurements of tumor cell Ki67 expression a”
Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry (2013, background): “– The Ki-67 percentage score is defined as the percentage of positively stained tumor cells among the total number of malignant cells assessed [11].”
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. (2011, background): “(6), 17 of the 18 studies that included more than 200 patients showed statistically significant association between Ki67 and prognosis providing compelling evidence for a biological relationship, but the cutoffs to distinguish “Ki67 high” from “Ki67 low” varied from 1% to 28.”